NCT02371226 - Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

January 23, 2017

Study Completion Date

February 1, 2017

Conditions

Mucopolysaccharidosis I

Interventions

DRUG

AGT-181 (HIRMAb-IDUA)

intravenous infusion over 3-4 hours

Trial Locations (6)

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

Emory Healthcare, Decatur

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

University of Utah Hospital, Salt Lake City

Children's Hospital of Orange County, Orange

Children's Hospital Oakland, Oakland